title: Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.
abstract: B-Raf(V600E) inhibitors have been suggested to promote tumor regression with the help of host immunity, but this hypothesis has not been examined directly in detail. In this study, we profiled immunologic changes in the tumor microenvironment and tumor-infiltrating lymphocytes (TIL) in a B-RafV600E/Pten-driven murine model of melanoma after administration of the B-Raf(V600E) small molecule inhibitor PLX4720. In this model, we found that as tumors developed, they gradually acquired immunosuppressive features, including accumulation of regulatory T cells (Treg) and CD11b(+)/Gr-1(+) myeloid cells and loss of Th1 effector functions on CD4(+) TILs, such as CD40L and IFNγ expression. PLX4720 administration promoted development of a more immune stimulatory microenvironment associated with a relative increase in CD40L and IFNγ expression on intratumoral CD4(+) TILs and a reduced accumulation of Tregs and CD11b(+)/Gr-1(+) myeloid cells. Strikingly, CD40L or IFNγ blockade compromised the ability of PLX4720 to inhibit melanoma growth. Supporting this result, agonistic CD40 antibody was sufficient to evoke antitumor immunity and suppress tumor growth in tumor-bearing mice. Taken together, our results establish the critical role of immune-related changes, with key contributions for CD40L and IFNγ signaling in the antitumor responses triggered in vivo by B-Raf(V600E) inhibitors.
authors.affiliation: Authors' Affiliations: Departments of Immunobiology, Dermatology, and Pathology, Yale University School of Medicine, New Haven, Connecticut; and Howard Hughes Medical Institute, Chevy Chase, Maryland.
authors.forename: Ping-Chih
authors.initials: PC
authors.lastname: Ho
authors.affiliation: Authors' Affiliations: Departments of Immunobiology, Dermatology, and Pathology, Yale University School of Medicine, New Haven, Connecticut; and Howard Hughes Medical Institute, Chevy Chase, MarylandAuthors' Affiliations: Departments of Immunobiology, Dermatology, and Pathology, Yale University School of Medicine, New Haven, Connecticut; and Howard Hughes Medical Institute, Chevy Chase, Maryland.
authors.forename: Katrina M
authors.initials: KM
authors.lastname: Meeth
authors.affiliation: Authors' Affiliations: Departments of Immunobiology, Dermatology, and Pathology, Yale University School of Medicine, New Haven, Connecticut; and Howard Hughes Medical Institute, Chevy Chase, MarylandAuthors' Affiliations: Departments of Immunobiology, Dermatology, and Pathology, Yale University School of Medicine, New Haven, Connecticut; and Howard Hughes Medical Institute, Chevy Chase, Maryland.
authors.forename: Yao-Chen
authors.initials: YC
authors.lastname: Tsui
authors.affiliation: Authors' Affiliations: Departments of Immunobiology, Dermatology, and Pathology, Yale University School of Medicine, New Haven, Connecticut; and Howard Hughes Medical Institute, Chevy Chase, Maryland.
authors.forename: Bhaskar
authors.initials: B
authors.lastname: Srivastava
authors.affiliation: Authors' Affiliations: Departments of Immunobiology, Dermatology, and Pathology, Yale University School of Medicine, New Haven, Connecticut; and Howard Hughes Medical Institute, Chevy Chase, Maryland.
authors.forename: Marcus W
authors.initials: MW
authors.lastname: Bosenberg
authors.affiliation: Authors' Affiliations: Departments of Immunobiology, Dermatology, and Pathology, Yale University School of Medicine, New Haven, Connecticut; and Howard Hughes Medical Institute, Chevy Chase, MarylandAuthors' Affiliations: Departments of Immunobiology, Dermatology, and Pathology, Yale University School of Medicine, New Haven, Connecticut; and Howard Hughes Medical Institute, Chevy Chase, Maryland susan.kaech@yale.edu.
authors.forename: Susan M
authors.initials: SM
authors.lastname: Kaech
mesh_terms: D000818:Animals; D000938:Antigen-Presenting Cells / Q000187:drug effects / Q000276:immunology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D023201:CD40 Ligand / Q000502:physiology*; D004354:Drug Screening Assays, Antitumor; D007211:Indoles / Q000494:pharmacology*; D007371:Interferon-gamma / Q000502:physiology*; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D008546:Melanoma, Experimental / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D020125:Mutation, Missense; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology*; D059016:Tumor Microenvironment / Q000276:immunology
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; C528407:PLX 4720; D013449:Sulfonamides; D023201:CD40 Ligand; D007371:Interferon-gamma; C482120:Braf protein, mouse; D048493:Proto-Oncogene Proteins B-raf
references.citation: Eur J Immunol. 2000 May;30(5):1263-71
references.pmid: 10820371
references.citation: Science. 2011 Mar 25;331(6024):1612-6
references.pmid: 21436454
references.citation: Surgery. 2011 Mar;149(3):336-46
references.pmid: 20875655
references.citation: Nat Rev Immunol. 2008 Dec;8(12):958-69
references.pmid: 19029990
references.citation: J Immunother. 2010 Oct;33(8):769-79
references.pmid: 20842060
references.citation: J Immunol. 2010 Apr 1;184(7):3394-400
references.pmid: 20200275
references.citation: Cancer Cell. 2011 Dec 13;20(6):741-54
references.pmid: 22172720
references.citation: N Engl J Med. 2013 Jul 11;369(2):122-33
references.pmid: 23724867
references.citation: Oncoimmunology. 2012 Aug 1;1(5):609-617
references.pmid: 22934253
references.citation: Cancer Res. 2012 Aug 15;72(16):3928-37
references.pmid: 22693252
references.citation: Immunity. 2008 Dec 19;29(6):934-46
references.pmid: 19062317
references.citation: N Engl J Med. 2012 Feb 23;366(8):707-14
references.pmid: 22356324
references.citation: Br J Cancer. 1986 Oct;54(4):615-22
references.pmid: 3535863
references.citation: Clin Cancer Res. 2003 Jan;9(1):84-92
references.pmid: 12538455
references.citation: Clin Cancer Res. 2012 Mar 1;18(5):1386-94
references.pmid: 22156613
references.citation: J Mol Cell Biol. 2013 Jun;5(3):207-9
references.pmid: 23532593
references.citation: J Clin Invest. 2013 May;123(5):1999-2010
references.pmid: 23619361
references.citation: Nat Rev Immunol. 2012 Jan 20;12(2):136-48
references.pmid: 22266691
references.citation: Lancet Oncol. 2013 Feb;14(2):e60-9
references.pmid: 23369684
references.citation: Clin Cancer Res. 2013 Feb 1;19(3):598-609
references.pmid: 23095323
references.citation: EJNMMI Res. 2012 May 31;2(1):22
references.pmid: 22651703
references.citation: J Clin Invest. 2013 Mar;123(3):1371-81
references.pmid: 23454771
references.citation: Clin Cancer Res. 2012 Oct 1;18(19):5329-40
references.pmid: 22850568
references.citation: Genes Dev. 2011 Dec 15;25(24):2559-72
references.pmid: 22190457
references.citation: J Clin Invest. 2011 Jun;121(6):2350-60
references.pmid: 21555851
references.citation: Nat Rev Immunol. 2011 Oct 14;11(11):723-37
references.pmid: 21997792
references.citation: Immunity. 2007 Oct;27(4):670-84
references.pmid: 17950003
references.citation: Cancer Res. 2010 Jul 1;70(13):5213-9
references.pmid: 20551059
references.citation: Cancer Cell. 2013 Mar 18;23(3):302-15
references.pmid: 23477830
references.citation: J Exp Med. 2010 Mar 15;207(3):651-67
references.pmid: 20156973
references.citation: Clin Cancer Res. 2013 Mar 1;19(5):1035-43
references.pmid: 23460534
references.citation: Nat Rev Drug Discov. 2012 Nov;11(11):873-86
references.pmid: 23060265
references.citation: Trends Immunol. 2012 Jul;33(7):364-72
references.pmid: 22445288
references.citation: Clin Cancer Res. 2013 Jan 15;19(2):393-403
references.pmid: 23204132
references.citation: Immunity. 2013 Jul 25;39(1):49-60
references.pmid: 23890063
references.citation: Semin Oncol. 2010 Oct;37(5):473-84
references.pmid: 21074063
references.citation: Am J Pathol. 2012 Sep;181(3):785-94
references.pmid: 22796458
references.citation: J Immunol. 2012 Aug 15;189(4):1708-16
references.pmid: 22798683
references.citation: Annu Rev Immunol. 2013;31:259-83
references.pmid: 23298210
references.citation: J Clin Invest. 2011 Dec;121(12):4746-57
references.pmid: 22056381
references.citation: Cancer Res. 2012 Jul 1;72(13):3125-30
references.pmid: 22721837
references.citation: Oncotarget. 2013 Apr;4(4):584-99
references.pmid: 23603840
references.citation: N Engl J Med. 2012 Nov;367(18):1694-703
references.pmid: 23020132
references.citation: Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5205-10
references.pmid: 9560254
references.citation: Nature. 2013 Feb 21;494(7437):361-5
references.pmid: 23376950
references.citation: J Leukoc Biol. 2010 Mar;87(3):477-85
references.pmid: 19952354
references.citation: Cancer Cell. 2010 Nov 16;18(5):485-98
references.pmid: 21035406
references.citation: N Engl J Med. 2008 Jun 19;358(25):2698-703
references.pmid: 18565862
references.citation: Nat Genet. 2009 May;41(5):544-52
references.pmid: 19282848
references.citation: Clin Cancer Res. 2013 Mar 1;19(5):1225-31
references.pmid: 23307859